ClinicalTrials.gg
TerminatedNCT04755244Updated Nov 27, 2024

A Study of Evorpacept (ALX148) With Venetoclax and Azacitidine for Acute Myeloid Leukemia (ASPEN-05)

A Phase 1 interventional study of evorpacept and venetoclax in Acute Myeloid Leukemia and AML, Adult, sponsored by ALX Oncology Inc.. Terminated at 5 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-11-27.

Sponsored by ALX Oncology Inc. · Phase 1, Interventional, and Treatment

Why this study was terminated
While intended to be a Phase 1/2 clinical study, the study never moved forward to Phase 2.

From the registry’s dates

  • Primary completion was May 2023, 3 years 6 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
14
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 2,137 studies in Leukemia, Myeloid, Acute with a site in United States — 312 open to participants now, 466 under way, 24 of them phase 3. Leukemia, Myeloid, Acute · United States.

Enrollment
1,490th of 1,907
14 · median 35
Started
2021
with 90 others
Phase 1
772 of 2,137
130 open now
Registered
1,735th of 2,137
by date

Among the 2,137 studies in Leukemia, Myeloid, Acute with a site in United States, this one is the 1,490th largest by enrollment of the 1,907 interventional ones that give a count, is one of 91 that started in 2021, is one of 772 in phase 1, and was the 1,735th registered.

Leukemia, Myeloid, Acute

3,669 studies on the registry are indexed under Leukemia, Myeloid, Acute; 817 are open to participants now.

Browse Leukemia, Myeloid, Acute studies →

Open to participants now

312 of the 2,137 studies in Leukemia, Myeloid, Acute with a site in United States are open now. Recruiting first, the newest first:

307 more — sign in →

All 312 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 625 Leukemia, Myeloid, Acute studies recruiting now, 363 (58%) set no upper age limit and 222 (36%) stop at 75 or younger; 145 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 2,137 studies in Leukemia, Myeloid, Acute with a site in United States, or all of them as a file.
02

Study summary

This Phase 1/2 clinical study will evaluate evorpacept (ALX148) in combination with venetoclax and azacitidine for the treatment of patients with acute myeloid leukemia (AML).

Read the detailed description

The Phase 1 will consist of a dose escalation of evorpacept (ALX148) in combination with venetoclax and azacitidine to evaluate safety and tolerability, and to identify the recommended Phase 2 dose of evorpacept (ALX148) in combination with venetoclax and azacitidine. The Phase 2 will evaluate the efficacy of evorpacept (ALX148) in combination with venetoclax and azacitidine for patients with AML. While intended to be a Phase 1/2 clinical study, the study never moved forward to Phase 2.

03

Conditions studied

  • Acute Myeloid Leukemia
  • AML, Adult

Keywords

  • ALX148
  • CD47
  • SIRPalpha
  • azacitidine
  • venetoclax
  • evorpacept
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • or histologically confirmed diagnosis of or newly diagnosed AML per WHO 2016 classification.
  • Phase 1a: AML that is relapsed/refractory or that is previously untreated in patients not considered suitable for intensive induction therapy.
  • Phase 1b: AML that is relapsed/refractory after prior treatment with a HMA-based regimen.
  • Phase 2: Previously untreated AML in patients who are not considered suitable candidates for intensive induction therapy.
  • Adequate renal and liver function.
  • Age ≥18 years.
  • Adequate performance status.

Exclusion criteria

Exclusion Criteria:

  • In Phase 1a and 1b, patients that have undergone prior must be at least 3 months post-HSCT, without uncontrolled (GVHD). For Phase 2, patients that have undergone prior allo-HSCT are excluded.
  • Patients with newly diagnosed AML with favorable risk cytogenetics such as t(8;21), inv(16), or t(16;16) as per the NCCN Guidelines Version 3, 2019 for AML.
  • Patients with acute promyelocytic leukemia (APL).
  • Prior treatment with any anti-7 or anti-SIRPalpha (signal regulatory protein alpha) agent.
  • Known active viral infections, including and C, (HIV), acquired immunodeficiency syndrome (AIDS) related illness, or SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2).
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
14 participants (actual)

Study arms

  • Experimental
    evorpacept (ALX148) + venetoclax + azacitidine

    Phase 1a: Participants will receive escalating doses of evorpacept (ALX148) in combination with venetoclax and azacitidine Phase 1b/2: Participants will receive evorpacept (ALX148) at the recommended Phase 2 dose in combination with venetoclax and azacitidine.

    Drug: evorpacept · Drug: venetoclax · Drug: azacitidine

Interventions

  • Fusion protein that blocks CD47-SIRPalpha pathway

    Also known as: ALX148

  • BCL-2 inhibitor

    Also known as: Venclexta

  • Hypomethylating agent (HMA)

    Also known as: Vidaza

06

What researchers measure

Primary outcomes

  1. Phase 1: Dose Limiting Toxicities (DLT)

    Number of participants with a DLT

    Time frame: Up to 28 days

  2. Phase 2: Composite complete remission rate (CRc)

    Number of participants achieving a complete remission (CR) and complete remission with incomplete hematologic recovery (CRi) per European LeukemiaNet (ELN) 2017 criteria

    Time frame: Approximately 6 months

07

Study locations

5 sites
  • Northwestern University Feinberg School of Medicine
    Chicago, Illinois 60611, United States
  • Roswell Park Comprehensive Cancer Center
    Buffalo, New York 14263, United States
  • Duke University Medical Center
    Durham, North Carolina 27710, United States
  • Vanderbilt University Medical Center
    Nashville, Tennessee 37203, United States
  • University of Texas MD Anderson Cancer Center
    Houston, Texas 77030, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2021 to primary completion in May 2023, 24 months.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 11, 2021
First posted
Feb 16, 2021
StartActual
May 5, 2021
Primary completionActual
May 5, 2023
CompletionActual
Aug 16, 2023
Last update
Nov 27, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 27, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04755244
Lead sponsor
ALX Oncology Inc.
Responsible party
Sponsor
First posted
Feb 16, 2021
Start date
May 5, 2021
Primary completion
May 5, 2023
Completion
Aug 16, 2023
Last update
Nov 27, 2024

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Aug 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: ALX148

Start the discussion